Blood Pressure and Risk of Atrial Fibrillation: A Mendelian Randomization Study
Matthew C. Hyman,
Michael G Levin,
Marios K. Georgakis,
Neil M Davies,
Francis E Marchlinski,
Scott M Damrauer
Posted 29 Jul 2020
medRxiv DOI: 10.1101/2020.07.26.20162339
Posted 29 Jul 2020
Abstract Importance: Observational studies have shown an association between hypertension and atrial fibrillation (AF). Aggressive blood pressure management in patients with known AF reduces overall arrhythmia burden, but it remains unclear whether hypertension is causative for AF. Objective: The primary objective of this study was to investigate the relationship between blood pressure and risk of AF using genetic proxies for blood pressure within a Mendelian randomization (MR) framework. We secondarily explored the relationship between genetically proxied use of anti-hypertensive drugs and risk of AF. Design: Two-sample MR was performed using an inverse-variance weighted meta-analysis with weighted median MR and Egger intercept tests performed as sensitivity analyses. Genetic proxies for the anti-hypertensive drug classes were used to investigate the impact of these therapies on the risk of AF. Setting: International Consortium of Blood Pressure, UK Biobank and Atrial Fibrillation Genetics Consortium. Participants: Summary statistics for systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP) were obtained from the International Consortium of Blood Pressure and the UK Biobank discovery analysis (>750,000 individuals of European ancestry). Summary statistics for AF were obtained from the 2018 Atrial Fibrillation Genetics Consortium multi-ethnic GWAS (>65,000 AF cases and >522,000 referents). Exposure: Genetically predicted SBP, DBP and PP as quantified by risk scores. Main Outcome: Odds ratio for AF per 10 mmHg increase in genetically proxied blood pressure. Results: Ten mmHg increases in genetically proxied SBP, DBP or PP were associated with increased odds of AF (SBP: OR 1.17, 95% CI 1.11-1.22, p=1x10-11; DBP: OR 1.25, 95% CI 1.16-1.35, p=3x10-8; PP: OR 1.1, 95% CI 1.0-1.2, p=0.05). Ten mmHg decreases in SBP estimated by genetic proxies of anti-hypertensive medications showed calcium channel blockers (OR 0.66, 95% CI 0.57-0.76, p=8x10-9) and beta-blockers (OR 0.61, 95% CI 0.46-0.81, p=6x10-4) decreased the risk of AF. Conclusions and Relevance: Blood pressure-increasing genetic variants were associated with increased risk of AF, consistent with a causal relationship between blood pressure and AF. These data support the concept that blood pressure reduction through pharmacologic intervention, and specifically calcium channel blockade or beta blockade could reduce the risk of AF.
- Downloaded 231 times
- Download rankings, all-time:
- Site-wide: 112,372
- In cardiovascular medicine: 250
- Year to date:
- Site-wide: 74,366
- Since beginning of last month:
- Site-wide: 76,528
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!